Combined analysis of three lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers

International Journal of Cancer

Volumn 132, Issue 7, 2013, Pages 1556-1564

  Talseth Palmer, Bente A ^a,b   Wijnen, Juul T ^c   Brenne, Ingvild S ^b,d   Jagmohan Changur, Shantie ^c   Barker, Daniel ^b,e   Ashton, Katie A ^a,b   Tops, Carli M ^c   Evans, Tiffany Jane ^a,b   McPhillips, Mary ^f   Groombridge, Claire ^g   Suchy, Janina ^h   Kurzawski, Grzegorz ^h   Spigelman, Allan ⁱ   Møller, Pål ^j   Morreau, Hans M ^c   Van Wezel, Tom ^c   Lubinski, Jan ^h   Vasen, Hans F A ^k   Scott, Rodney J ^a,b,f  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TROMSØ   (Norway)

^e UNIVERSITY OF NEWCASTLE   (Australia)

^f JOHN HUNTER HOSPITAL   (Australia)

^g Hunter Family Cancer Service   (Australia)

^h POMERANIAN MEDICAL UNIVERSITY   (Poland)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

^k Dutch Foundation for the Detection of Hereditary Tumors   (Netherlands)

more..

Author keywords

11q23.1; 8q23.3; CRC susceptibility loci; lynch syndrome

Indexed keywords

PROTEIN MLH1;

ADULT; AGED; ALLELE; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 11Q; CHROMOSOME 8Q; CHROMOSOME ANALYSIS; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FAMILY STUDY; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MLH1 GENE; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; POPULATION GENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 8; COHORT STUDIES; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FEMALE; FOLLOW-UP STUDIES; GENES, MODIFIER; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 84873096992     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27843     Document Type: Article

References (44)

1. Miyaki M, Konishi M, Tanaka K, et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997; 17: 271-2.
2. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 2009; 41: 112-7.
3. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75: 1027-38.
4. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368: 258-61.
5. Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994; 371: 75-80.
6. Obermair A, Youlden DR, Young JP, et al. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer 2010; 127: 2678-84.
7. Alarcon F, Lasset C, Carayol J, et al. Estimating cancer risk in HNPCC by the GRL method. Eur J Hum Genet 2007; 15: 831-6.
8. Lawes DA, SenGupta SB, Boulos PB,. Pathogenesis and clinical management of hereditary non-polyposis colorectal cancer. Br J Surg 2002; 89: 1357-69.
9. Lu K,. Endometrial cancer in women with HNPCC. Int J Gynecol Cancer 2005; 15: 400-1.
10. Ramsoekh D, Wagner A, van Leerdam ME, et al. Cancer risk in MLH1, MSH2 and MSH6 mutation carriers: different risk profiles may influence clinical management. Hereditary Cancer Clin Practice 2009; 7: 17.
11. Kastrinos F, Stoffel EM, Balmana J, et al. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States. Cancer Epidemiol Biomarkers Prevent 2008; 17: 2044-51.
12. Jones JS, Chi X, Gu X, et al. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 2004; 10: 5845-9.
13. Talseth BA, Meldrum C, Suchy J, et al. Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53. Int J Cancer 2006; 118: 2479-84.
14. Bala S, Peltomaki P,. CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res 2001; 61: 6042-5.
15. Kruger S, Engel C, Bier A, et al. Absence of association between cyclin D1 (CCND1) G870A polymorphism and age of onset in hereditary nonpolyposis colorectal cancer. Cancer Lett 2006; 236: 191-7.
16. Houlston RS, Cheadle J, Dobbins SE, et al. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet 2010; 42: 973-7.
17. Houlston RS, Webb E, Broderick P, et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet 2008; 40: 1426-35.
18. Broderick P, Carvajal-Carmona L, Pittman AM, et al. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet 2007; 39: 1315-7.
19. Tenesa A, Farrington SM, Prendergast JG, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 2008; 40: 631-7.
20. Tomlinson IP, Webb E, Carvajal-Carmona L, et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 2008; 40: 623-30.
21. Wijnen JT, Brohet RM, van Eijk R, et al. Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in lynch syndrome. Gastroenterology 2009; 136: 131-7.
22. Talseth-Palmer BA, Brenne IS, Ashton KA, et al. Colorectal cancer susceptibility loci on chromosome 8q23.3 and 11q23.1 as modifiers for disease expression in lynch syndrome. J Med Genet 2011; 48: 279-84.
23. Giraldez MD, Lopez-Doriga A, Bujanda L, et al. Susceptibility genetic variants associated with early-onset colorectal cancer. Carcinogenesis 2012; 33: 613-9.
24. Houlle S, Charbonnier F, Houivet E, et al. Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers. Eur J Hum Genet 2011; 19: 887-92.
25. Pittman AM, Webb E, Carvajal-Carmona L, et al. Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer. Hum Mol Genet 2008; 17: 3720-7.
26. Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007; 44: 353-62.
27. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006; 296: 1507-17.
28. Janavicius R, Elsakov P,. Novel germline MSH2 mutation in Lynch syndrome patient surviving multiple cancers. Hereditary Cancer Clin Practice 2012; 10: 1.
29. Niittymaki I, Tuupanen S, Li Y, et al. Systematic search for enhancer elements and somatic allelic imbalance at seven low-penetrance colorectal cancer predisposition loci. BMC Med Genet 2011; 12: 23.
30. Abuli A, Bessa X, Gonzalez JR, et al. Susceptibility genetic variants associated with colorectal cancer risk correlate with cancer phenotype. Gastroenterology 2010; 139: 788-96
31. Abuli A, Bessa X, Gonzalez JR, et al. Susceptibility genetic variants associated with colorectal cancer risk correlate with cancer phenotype. Gastroenterology 2010; 96: e1-6.
32. Dong Z, Zhang JT,. Initiation factor eIF3 and regulation of mRNA translation, cell growth, and cancer. Crit Rev Oncol Hematol 2006; 59: 169-80.
33. Pittman AM, Naranjo S, Jalava SE, et al. Allelic variation at the 8q23.3 colorectal cancer risk locus functions as a cis-acting regulator of EIF3H. PLoS Genet 2010; 6.
34. Carvajal-Carmona LG, Cazier JB, Jones AM, et al. Fine-mapping of colorectal cancer susceptibility loci at 8q23.3, 16q22.1 and 19q13.11: refinement of association signals and use of in silico analysis to suggest functional variation and unexpected candidate target genes. Hum Mol Genet 2011; 20: 2879-88.
35. Hill WG, Goddard ME, Visscher PM,. Data and theory point to mainly additive genetic variance for complex traits. PLoS Genet 2008; 4: e1000008.
36. Peltola T, Marttinen P, Jula A, et al. Bayesian variable selection in searching for additive and dominant effects in genome-wide data. PloS One 2012; 7: e29115.
37. Middeldorp A, Jagmohan-Changur S, van Eijk R, et al. Enrichment of low penetrance susceptibility loci in a Dutch familial colorectal cancer cohort. Cancer Epidemiol Biomarkers Prev 2009; 18: 3062-7.
38. Gerke J, Lorenz K, Cohen B,. Genetic interactions between transcription factors cause natural variation in yeast. Science 2009; 323: 498-501.
39. Maher B,. Personal genomes: the case of the missing heritability. Nature 2008; 456: 18-21.
40. Savinainen KJ, Linja MJ, Saramaki OR, et al. Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer 2004; 90: 1041-6.
41. Vasen HF, Abdirahman M, Brohet R, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 2010; 138: 2300-6.
42. Plaschke J, Engel C, Kruger S, et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German hereditary nonpolyposis colorectal cancer consortium. J Clin Oncol 2004; 22: 4486-94.
43. Niittymaki I, Kaasinen E, Tuupanen S, et al. Low-penetrance susceptibility variants in familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 2010; 19: 1478-83.
44. Int.-HapMap-Consortium. The international HapMap project. Nature 2003; 426: 789-96.